Business
ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits CE Mark Application
FDA 510(k) application submitted to allow marketing of the ARC-EX® System for home use in the United StatesCE Mark application filed with notified body to enable commercialization of the ARC-EX System in the European Union and other countries EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injur
About this update from Onward Medical N.v.
[{"type":"image","alt":"ONWARD Medical NV","displaySize":"","headline":null,"caption":"ONWARD Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CPLGUw1yVOurWsVIgzW3oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FDA 510(k) application submitted to allow marketing of the ARC-EX® System for home use in the United States","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"CE Mark application filed with notified body to enable commercialization of the ARC-EX System in the European Union and other countries","length":135,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":242,"olType":false},{"type":"text","content":"EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world.","length":936,"tagName":"p"},{"type":"text","content":"The ARC-EX System is the first and only FDA-cleared technology indicated to improve hand sensation and strength after SCI. Following the successful initial phase of its US launch to clinics, ONWARD is pursuing FDA clearance to expand marketing of the ARC-EX System for use at home. Strong early demand and positive feedback from users suggest the Company is on track to meet its 2025 expec...